PMID- 15764611
OWN - NLM
STAT- MEDLINE
DCOM- 20050825
LR  - 20220330
IS  - 0195-668X (Print)
IS  - 0195-668X (Linking)
VI  - 26
IP  - 9
DP  - 2005 May
TI  - Long-term outcome in relation to renal sympathetic activity in patients with 
      chronic heart failure.
PG  - 906-13
AB  - AIMS: Although cardiac sympathetic activation is associated with adverse outcome 
      in patients with chronic heart failure (CHF), the influence of renal sympathetic 
      activity on outcome is unknown. We assessed the hypothesis that renal 
      noradrenaline (NA) spillover is a predictor of the combined endpoint of all-cause 
      mortality and heart transplantation in CHF. METHODS AND RESULTS: Sixty-one 
      patients with CHF, New York Heart Association (NYHA) I-IV (66% NYHA III-IV), and 
      left ventricular ejection fraction (LVEF) 26+/-9% (mean+/-SD) were studied with 
      cardiac and renal catheterizations at baseline and followed for 5.5+/-3.7 years 
      (median 5.5 years, range 12 days to 11.6 years). Nineteen deaths and 13 cases of 
      heart transplantation were registered. Only renal NA spillover above median, 1.19 
      (interquartile range 0.77-1.43) nmol/min, was independently associated with an 
      increased relative risk (RR) of the combined endpoint (RR 3.1, 95% CI 1.2-7.6, 
      P=0.01) in a model also including total body NA spillover, LVEF, glomerular 
      filtration rate (GFR), renal blood flow, cardiac index, aetiology, and age. 
      CONCLUSION: Renal noradrenergic activation has a strong negative predictive value 
      on outcome independent of overall sympathetic activity, GFR, and LVEF. These 
      findings suggest that treatment regimens that further reduce renal noradrenergic 
      stimulation could be advantageous by improving survival in patients with CHF.
FAU - Petersson, Magnus
AU  - Petersson M
AD  - Department of Cardiology, The Cardiovascular Institute, Sahlgrenska University 
      Hospital, S-413 45 Goteborg, Sweden. magnus.petersson@wlab.gu.se
FAU - Friberg, Peter
AU  - Friberg P
FAU - Eisenhofer, Graeme
AU  - Eisenhofer G
FAU - Lambert, Gavin
AU  - Lambert G
FAU - Rundqvist, Bengt
AU  - Rundqvist B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20050310
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - X4W3ENH1CV (Norepinephrine)
SB  - IM
CIN - Eur Heart J. 2005 May;26(9):861-2. PMID: 15764614
MH  - Autonomic Nervous System Diseases/metabolism/*mortality
MH  - Chronic Disease
MH  - Disease-Free Survival
MH  - Female
MH  - Heart Failure/metabolism/*mortality/surgery
MH  - Heart Transplantation/*mortality
MH  - Humans
MH  - Kidney/*innervation/metabolism
MH  - Long-Term Care
MH  - Male
MH  - Middle Aged
MH  - Norepinephrine/*metabolism
MH  - Prognosis
MH  - Regression Analysis
EDAT- 2005/03/15 09:00
MHDA- 2005/08/27 09:00
CRDT- 2005/03/15 09:00
PHST- 2005/03/15 09:00 [pubmed]
PHST- 2005/08/27 09:00 [medline]
PHST- 2005/03/15 09:00 [entrez]
AID - ehi184 [pii]
AID - 10.1093/eurheartj/ehi184 [doi]
PST - ppublish
SO  - Eur Heart J. 2005 May;26(9):906-13. doi: 10.1093/eurheartj/ehi184. Epub 2005 Mar 
      10.